IRF1 and neoplasm: We observe that patients who received neoadjuvant therapy have increased activity of the Trail pathway, possibly as a consequence of the more effective killing of tumor cells, and of the TFs IRF1, responsible for stimulating recruitment of antitumor immune cells,39 and NFATC2, a marker of T cell activation, which could explain the stronger immune response of these patients (Figure S9).